Can we use MTX+MMF to treat active #TAK rather than CYC? ➡️MTX+MMF vs CYC/AZA over 52W MTX+MMF had: ⬆️Better efficacy in inducing & maintaining remission ❕Comparable safety to CYC/AZA ⏩This combination may prove preferable to using CYC Ab1696 #ACR24 @RheumNow https://t.co/S0A8YNk3qL

• https://x.com/DrMiniDey/status/1858218295322665117/photo/1

Post hoc analysis of INVIGORATE-1 trial evaluated predictors of ASAS40 response in axSpA pts who received IV SEC ⬆️back pain, long dse duration, ⬇️BMI: assoc w/ ⬆️ clinical response BL enthesitis, older age, ⬆️dse activity: assoc w/ ⬇️ clinical response @RheumNow #ACR24 abs1482 https://t.co/528A5lXVKl

• https://x.com/RHEUMarampa/status/1858210259434897823/photo/1
• https://x.com/RHEUMarampa/status/1858210259434897823/photo/1

This study by Dr. UGazel et al shows that cervical DISH in SpA is similar to the general population. Of note, HLAB27+ axSpA pts had more DISH while PsA pts had DISH if they were HLaB27(-) @RheumNow #ACR24 abs1447 https://t.co/GtcvxVSb8B

• https://x.com/RHEUMarampa/status/1858199028069961871/photo/1

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB

• Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal…
• https://x.com/RichardPAConway/status/1858185580116328614/photo/1

Are biosimilar multi-switches an issue? real world data: DANBIO 🇩🇰 biosimilar to biosimilar switch having already had a switch prior ('previous ADAo') did not increase cessation The risk of biosimilar switching on immunogenicity is greatly overstated #ACR24 ABST1000 @RheumNow https://t.co/1yAfZrrNd0

• https://x.com/drdavidliew/status/1858180360288526800/photo/1

New agent on the block: Bimekizumab IL-17A/F inhibitor Promising clinical data in SpA - what about imaging findings? Dramatic reductions in MRI activity at SI joints seen in BKZ pt, esp when compared to trajectory of PBO pt before cross-over @RheumNow #ACR24 Abst #1757 https://t.co/ACLJx5XkyN

• https://x.com/Dr_Brian_MD/status/1858168067844383139/photo/1

A systematic review reveals significant sex-related differences in efficacy and safety outcomes in axial spondyloarthritis (axSpA) trials. Males show higher response rates to advanced therapies compared to females. Out of 79 RCTs, only a fraction reported sex-disaggregated data.… https://t.co/dkMRK4ZYHF

• https://x.com/i/web/status/1858166957427597483

Does psoriasis (Pso) affect radiographic progression in ankylosing spondylitis (AS)? A study comparing radiographic spine assessment in AS patients with and without Pso reveals no significant differences in structural lesions. Male gender is a key factor in structural… https://t.co/z34FjHtjEJ

• https://x.com/i/web/status/1858170733232300285

A meta-analysis of 11 randomized trials shows no significant difference in efficacy of bDMARDs for early vs. established axial spondyloarthritis (axSpA). Treating at different stages yields comparable short-term outcomes. Abstr#1468 #Spondyloarthritis #RheumatologyResearch… https://t.co/QYuTcVj2m1 https://t.co/ADzEEbCvUM

• https://x.com/i/web/status/1858163192071065944
• https://x.com/synovialjoints/status/1858163192071065944/photo/1

Dietary changes are intermittent fasting are common in axial spondylarthritis (axSpA) patients, possibly reducing inflammation. A study found 55% currently on a diet and 31% fasting. Many believe these practices improve disease activity. Abstr#1459 #diet #axSpA @RheumNow #ACR24